GlassScriptPhysician profile
Elijah N Gilbert
NPI 1871785493
$1,865.17
in general payments reported to CMS, 2019-2025
24 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $94.43 · 2021: $213 · 2022: $298 · 2023: $251 · 2024: $291 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $820.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $336.19 | 2019-2023 | |
| Pfizer INC. | $260.57 | 2021-2024 | |
| Evofem Biosciences, INC. | $204.24 | 2022-2025 | Phexxi, Solosec, Phexx |
| Bayer Healthcare Pharmaceuticals INC. | $134.34 | 2019-2023 | |
| Organon LLC | $121.67 | 2021-2025 | Nexplanon |
| Duchesnay USA Incorporated | $109.24 | 2019 | |
| Daiichi Sankyo INC. | $79.78 | 2019-2022 | |
| Astellas Pharma US INC | $76.45 | 2024-2025 | Veozah |
| Allergan, INC. | $75.46 | 2019-2020 | |
| Davol INC. | $55.58 | 2019-2025 | Arista |
| Sumitomo Pharma America, INC. | $49.70 | 2023-2024 | Myfembree |
| Myovant Sciences INC. | $48.55 | 2022 | |
| Biogen, INC. | $46.11 | 2024 | |
| Smith+Nephew, INC. | $37.73 | 2019-2025 | Pico 14 |
| Hologic Sales and Service, LLC | $37.58 | 2020-2023 | Aptima |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $37.06 | 2025 | Slynd |
| Mayne Pharma Commercial LLC | $33.83 | 2022-2023 | |
| Coopersurgical, INC. | $32.16 | 2019-2023 | Paragard T 380a |
| Millicent US INC | $17.83 | 2025 | Femlyv, Intrarosa |
| Novo Nordisk INC | $15.90 | 2024 | Ozempic, Rybelsus |
| Roche Diagnostics Corporation | $15.38 | 2019 | |
| Aspira Women'S Health INC | $13.95 | 2024 | Ova1 |
| Minerva Surgical, INC | $13.41 | 2024 | |
| Mylan Pharmaceuticals INC. | $12.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elijah Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.